Opus Genetics to Participate in Upcoming Investment Conferences

Rhea-AI Summary

Opus Genetics (Nasdaq: IRD) announced management will participate in two investor conferences in early December 2025. Ash Jayagopal, PhD, MBA, Chief Scientific and Development Officer, will appear in a fireside chat at BTIG 5th Annual Ophthalmology Day (Virtual) on December 1, 2025 at 1:00 p.m. ET. George Magrath, M.D., Chief Executive Officer, will appear in a fireside chat at Piper Sandler 37th Annual Healthcare Conference on December 2, 2025 at 10:00 a.m. ET in New York.

A link to the live and archived webcast for the Piper Sandler presentation is available on Opus Genetics' Investors > Events web page.

RESEARCH TRIANGLE PARK, N.C., Nov. 20, 2025 (GLOBE NEWSWIRE) -- Opus Genetics, Inc. (Nasdaq: IRD) (the “Company” or “Opus Genetics”), a clinical-stage biopharmaceutical company developing gene therapies to restore vision and prevent blindness in patients with inherited retinal diseases (IRDs), announced today that management will participate in the following investor conferences.

BTIG 5^th Annual Ophthalmology Day (Virtual): Ash Jayagopal, PhD, MBA, Chief Scientific and Development Officer, will participate in a fireside chat on Monday, December 1, 2025, at 1:00 p.m. ET.

Piper Sandler 37th Annual Healthcare Conference: George Magrath, M.D., Chief Executive Officer, will participate in a fireside chat on Tuesday, December 2, 2025, at 10:00 a.m. ET in New York, NY.

A link to the live and archived webcast for the Piper Sandler conference may be accessed on Opus Genetics’ website under the Investors section: Events.

About Opus Genetics

Opus Genetics is a clinical-stage biopharmaceutical company developing gene therapies to restore vision and prevent blindness in patients with inherited retinal diseases (IRDs). The Company is developing durable, one-time treatments designed to address the underlying genetic causes of severe retinal disorders. The Company’s pipeline includes seven AAV-based programs, led by OPGx-LCA5 for LCA5-related mutations and OPGx-BEST1 for BEST1-related retinal degeneration, with additional candidates targeting RHO, RDH12, and MERTK. Opus Genetics is also advancing Phentolamine Ophthalmic Solution 0.75%, an approved small-molecule therapy for pharmacologically induced mydriasis, with additional indications in late-stage development for presbyopia and low-light visual disturbances following keratorefractive surgery. The Company is based in Research Triangle Park, NC. For more information, visit www.opusgtx.com.

Contacts:

Investors
Jenny Kobin
Remy Bernarda
IR Advisory Solutions
ir@opusgtx.com

Media
Kimberly Ha
KKH Advisors
917-291-5744
kimberly.ha@kkhadvisors.com

Source: Opus Genetics, Inc.

FAQ

When will Opus Genetics (IRD) present at BTIG 5th Annual Ophthalmology Day?

Opus Genetics will present virtually on December 1, 2025 at 1:00 p.m. ET (Ash Jayagopal, PhD, MBA).

When and where will Opus Genetics (IRD) present at Piper Sandler 37th Annual Healthcare Conference?

The Piper Sandler fireside chat is scheduled for December 2, 2025 at 10:00 a.m. ET in New York (George Magrath, M.D.).

How can investors watch the Opus Genetics (IRD) Piper Sandler presentation?

Investors can access the live and archived webcast via Opus Genetics' website under the Investors > Events section.

Who from Opus Genetics (IRD) will speak at the December 2025 investor conferences?

Ash Jayagopal, PhD, MBA will speak at BTIG (virtual) and George Magrath, M.D. will speak at Piper Sandler (New York).

Is the Piper Sandler Opus Genetics (IRD) webcast available after the event?

Yes, a link to the live and archived webcast for the Piper Sandler conference is posted on the company's Investors > Events web page.